A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis
Latest Information Update: 31 Mar 2025
At a glance
- Drugs MT 1013 (Primary) ; Etelcalcetide
- Indications Renal failure; Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Shaanxi Micot Technology Co
Most Recent Events
- 26 Mar 2025 Primary endpoint time frame changed from Weeks 20 to 27 to Weeks 22 to 27.
- 26 Mar 2025 Planned End Date changed from 1 Sep 2025 to 1 Mar 2026.
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.